1890-25-1

Usage

Synthesis Reference(s)

Tetrahedron Letters, 21, p. 4687, 1980 DOI: 10.1016/0040-4039(80)88094-4

Upstream product

• 4378-96-5 3,3'-cyclohexylidene-di-propionic acid 
• 108-94-1 cyclohexanone 
• 107-13-1 acrylonitrile 
• 30834-42-5 spiro[5.5]undec-1-en-3-one 
• 77419-46-6 C₁₀H₁₆O 
• 17065-15-5 1,1-Divinylcyclohexan 
• 256379-28-9 N-(3-methyl-2-pyridyl)-N-[(E)-3-phenyl-2-propenyl]amine 
• 4378-97-6 1,1-Bis-(β-cyan-ethyl)-cyclohexan 
• 6815-55-0 1-(cyclohexylidenemethyl)pyrrolidine 
• 78-94-4 methyl vinyl ketone 
• 2043-61-0 cyclohexanecarbaldehyde 
• 2658-60-8 1,1-bis(hydroxymethyl)cyclohexane 
• 1139-13-5 diethyl cyclohexane-1,1-dicarboxylate 
• 111-24-0 1,5-dibromo-pentane 

Downstream Products

• 4564-68-5 Dispiro<5.1.5.3>hexadecanon-(16) 
• 101593-47-9 spiro[5.5]undeca-1,4-dien-3-one-(2,4-dinitro-phenylhydrazone) 
• 307990-56-3 4-(spiro[5.5]undec-3-ylaminomethyl)benzoic acid methyl ester 
• 18244-47-8 spiro[5.5]undecane-3-carboxylic acid 
• 2126-94-5 spiro[5.5]undecan-3-amine hydrochloride 
• 356781-02-7 C₁₆H₂₃NO₂S 
• 3643-16-1 spiro<4.5>decan-2-one 
• 20127-08-6 2,2-pentamethylene-1,4-butanedicarboxylic acid 

Relevant academic research and scientific papers

Mn(III)-Based Oxidative Fragmentation-Cyclization Reactions of Unsaturated Cyclobutanols

Alylic cyclobutanols 1, 10, 21, 27, 32, 39, 51 and 58 are oxidatively fragmented by Mn(OAc)3*2H2O in EtOH to give tertiary radicals as shown in eq 1.These tertiary radicals undergo both 6-endo-cyclization to the α,β-unsaturated ketone to afford α-keto rad

Radical Carbonyl Umpolung Arylation via Dual Nickel Catalysis

The formation of carbon-carbon bonds lies at the heart of synthetic organic chemistry and is widely applied to construct complex drugs, polymers, and materials. Despite its importance, catalytic carbonyl arylation remains comparatively underdeveloped, due

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

Pichia stipitis OYE 2.6 variants with improved catalytic efficiencies from site-saturation mutagenesis libraries

An earlier directed evolution project using alkene reductase OYE 2.6 from Pichia stipitis yielded 13 active site variants with improved properties toward three homologous Baylis-Hillman adducts. Here, we probed the generality of these improvements by testing the wild-type and all 13 variants against a panel of 16 structurally-diverse electron-deficient alkenes. Several substrates were sterically demanding, and as hoped, creating additional active site volume yielded better conversions for these alkenes. The most impressive improvement was found for 2-butylidenecyclohexanone. The wild-type provided less than 20% conversion after 24 h; a triple mutant afforded more than 60% conversion in the same time period. Moreover, even wild-type OYE 2.6 can reduce cyclohexenones with very bulky 4-substituents efficiently.

Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2

Influenza A virus M2 (A/M2) forms a homotetrameric proton selective channel in the viral membrane. It has been the drug target of antiviral drugs such as amantadine and rimantadine. However, most of the current virulent influenza A viruses carry drug-resistant mutations alongside the drug binding site, such as S31N, V27A, and L26F, etc., each of which might be dominant in a given flu season. Among these mutations, the V27A mutation was prevalent among transmissible viruses under drug selection pressure. Until now, V27A has not been successfully targeted by small molecule inhibitors, despite years of extensive medicinal chemistry research efforts and high throughput screening. Guided by molecular dynamics (MD) simulation of drug binding and the influence of drug binding on the dynamics of A/M2 from earlier experimental studies, we designed a series of potent spirane amine inhibitors targeting not only WT, but also both A/M2-27A and L26F mutants with IC50s similar to that seen for amantadine's inhibition of the WT channel. The potencies of these inhibitors were further demonstrated in experimental binding and plaque reduction assays. These results demonstrate the power of MD simulations to probe the mechanism of drug binding as well as the ability to guide design of inhibitors of targets that had previously appeared to be undruggable.

SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF

The Spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof

N-SUBSTITUTED PHENYLACETAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

A compound represented by the formula: (I) wherein R1 represents a methoxy group, a hydroxyl group or a hydrogen atom; R2 represents a hydrogen atom, a C1-4 alkyl group, a C1-4 alkylcarbonyl group or an arylcarbonyl group; and D represents a group represented by the formula (A), (B) or (C) below. (A) (B) (C) This compound is useful as a therapeutic agent for a pain or inflammation induced by any one of various morbid conditions such as neuropathic pain, rheumatoid arthritis and osteoarthritis.

Pyrrolidine and thiazolidine compounds

Compounds of formula (I): wherein: X1 represents an atom or group selected from CR4aR4b, O, S(O)q1 and NR5, wherein R4a, R4b, q1 and R5 are as defined in the description, m1 represents zero or an integer from 1 to 4 inclusive, m2 represents an integer from 1 to 4 inclusive, n1 and n2, which may be identical or different, each represent an integer from 1 to 3 inclusive, R1 represents hydrogen or a group selected from carboxy, alkoxycarbonyl, optionally substituted carbamoyl and optionally substituted alkyl, R2 represents hydrogen or alkyl, Ak represents an optionally substituted alkylene chain, p represents zero, 1 or 2, R3 represents hydrogen or cyano, X2 and X3, which may be identical or different, each represent either S(O)q2, or CR6aR6b, wherein q2, R6a and R6b are as defined in the description, its optical isomers, where they exist, and its addition salts with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful as DPP-IV inhibitors.

Synthesis of cycloalkanones from dienes and allylamines through C-H and C-C bond activation catalyzed by a rhodium(I) complex

Formaldehyde in disguise: The allylic amine 1 is used as a masked form of formaldehyde in the rhodium-catalyzed cyclization of dienes 2. The reaction provides access to various cycloalkanones 3 through chelation-assisted C-H- and C-C-bond activation.